From genomics to clinic: the transformative impact of AI in pharmacogenomics and personalized medicine [0.03%]
从基因组学到临床：人工智能在药物基因组学和个性化医学中的变革性影响
Anantha Lakshmi Jakka,Ripsy Merrin Chacko,Mallikarjun Vasam et al.
Anantha Lakshmi Jakka et al.
At the crossroads of genomics and pharmacology, pharmacogenomics is revolutionizing healthcare by tailoring drug therapies to individual genetic profiles thereby reducing the risk of adverse drug reactions and propelling the field of precis...
Cancer genetics and response to oncolytic virus treatment for ovarian cancer [0.03%]
卵巢癌的癌症遗传学和溶瘤病毒治疗反应
Erin L Fletcher,Alison O Cudmore,Barbara C Vanderhyden
Erin L Fletcher
Ovarian cancers (OCs) are often defined as poorly immunogenic tumors that have low response rates to current immunotherapies and frequently develop resistance to chemotherapies. Oncolytic viruses (OVs) are an emerging therapeutic approach t...
Pharmacogenetic markers of PEG-asparaginase toxicity in Brazilian pediatric ALL: insights from a multicenter prospective cohort study [0.03%]
巴西儿童急性淋巴细胞 leukemia聚乙二醇天冬酰胺酶毒性药理基因标记物的多中心前瞻性队列研究见解
Daiane Keller Cecconello,Klerize Anecely de Souza Silva,Evelin Cristine Mendonça de Senna et al.
Daiane Keller Cecconello et al.
Aims: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Although PEG-asparaginase (PEG-ASNase) is a key drug in treatment, hypersensitivity reactions, pancreatitis, and silent inactivation remain maj...
The impact of GST genetic polymorphisms on the response to oxaliplatin-based chemotherapy and survival prognosis in gastric cancer patients [0.03%]
GST基因多态性对胃癌患者奥沙利铂为基础的化疗反应及预后影响研究
Jiaodi Zhang,Qi Jin,Tao Chen et al.
Jiaodi Zhang et al.
Aim: This study aimed to assess the impact of GSTP1, GSTM1, and GSTT1 polymorphisms on the response to oxaliplatin-based chemotherapy and survival outcomes in gastric cancer patients from Northwest China. ...
J F Vieira,I H Tassoni,M L Chaves et al.
J F Vieira et al.
The CYP2C19 gene encodes one of the main enzymes responsible for clopidogrel bioactivation, a widely prescribed antiplatelet prodrug. Due to its high polymorphism, clopidogrel response varies considerably, especially in carriers of nonfunct...
Sara Labay-Tejado,Mercè Brunet,Elena Milla
Sara Labay-Tejado
Glaucoma is a chronic, degenerative eye disease for which personalized diagnostic and therapeutic biomarkers are still lacking. Precision medicine offers a promising strategy to improve glaucoma management, and pharmacogenomics may play a k...
Characterizing models for delivery of pharmacogenomic testing: a scoping review [0.03%]
药学基因分型检测递送模型的特征：综述性研究
Zeina Waheed,Mary Bunka,Louisa Edwards et al.
Zeina Waheed et al.
Pharmacogenomic (PGx) testing can help guide medication prescribing for a wide range of health indications. The objective of this scoping review was to understand how PGx testing has been clinically implemented and learn from these experien...
ADIPOQ genotypes and haplotypes, circulating adiponectin levels and responsiveness to antihypertensive therapy in preeclampsia [0.03%]
ADIPOQ基因型和单倍体型、循环脂联素水平及重度子痫前期患者对降压治疗的反应性
Daniela A Pereira,Ricardo N F de Castro,Ana C Palei et al.
Daniela A Pereira et al.
Aims: We compared plasma adiponectin levels between patients with preeclampsia (PE) classified as responsive and nonresponsive to antihypertensive therapy; Moreover, we examined whether ADIPOQ SNPs rs17300539, rs266729,rs...
Laurence Tessier,Sophie St-Amour,Dorianne Simard et al.
Laurence Tessier et al.
Diabetes is a chronic disease that affects approximately 589 million people worldwide. Type 2 diabetes is one of its main forms (~90%) and manifests as hyperglycemia due to the resistance of myocytes and adipocytes to insulin. These are una...
Molecular markers of treatment irregularity of statins: influence of polymorphisms in SLCO1B1 and SLCO1B3 [0.03%]
他汀类药物治疗不规律的分子标志物：SLCO1B1和SLCO1B3多态性的影响
Jéssica Louise Benelli,Lisiane Smiderle,Silvana de Almeida et al.
Jéssica Louise Benelli et al.
Background and aims: The SLCO gene family encodes OATP-like transporters that interact with statins and may influence their efficacy. Consequently, these genes are key targets in pharmacogenetic studies, and associations ...